GILEAD SCIENCES INC (GILD)
@GILD.asset
$103.68
At close:
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
Figures
- Sector Healthcare
- Industry Biotechnology
- Index Nasdaq-100, S&P 500
- Market Cap $129.12 B
- Last Earnings Report Feb 28, 2025
- Price Reaction to Earnings Report -1.59%
- Enterprise Value $144.16 B
- Dividend Yield 0.03%
- P/E ratio 269.91
- Price/Sales ratio 4.50
- EV/Sales ratio 5.01
- Price/Book Value 6.72
- Revenue $28.75 B
- EBIT $1.39 B
- Net Income $0.48 B
- Gross Profit $22.50 B
- Free Cash Flow $10.30 B
- EBIT Margin 4.83%
- Gross Margin 78.26%
- FCF Margin 35.84%
- Return on Equity 2.49%
- Equity Ratio 32.62%
- Debt/Equity Ratio 2.07
- 6-month Performance 17.63%
- 12-month Performance 64.60%
- Trend reversal neutral
What the community is saying
| Nobody said anything, yet! Speak your mind and be the first to create a new topic. |